Soligenix Advances Orphan Drug Strategy with HyBryte for Rare Skin Cancer Treatment

Soligenix Inc. (NASDAQ: SNGX) is advancing a differentiated approach to orphan drug development, emphasizing a de-risked model focused on patient safety and capital efficiency, as highlighted in a recent citybiz feature. The company's lead candidate, HyBryte(TM), targets cutaneous T-cell lymphoma using visible light activation rather than traditional chemotherapy or UV-based therapies, with clinical data indicating faster response times and a favorable safety profile, while also supporting potential at-home treatment through telehealth-enabled delivery.

The company is nearing completion of a confirmatory Phase 3 study for HyBryte(TM), with interim analysis expected in early 2026 and top-line results later in the year, alongside supportive data showing strong patient response rates. Soligenix's broader strategy leverages regulatory incentives for orphan diseases and more than $60 million in non-dilutive funding to advance multiple pipeline candidates, including potential applications in psoriasis and autoimmune conditions, positioning the company for continued growth in rare disease therapeutics.

Soligenix's Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma. With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, the company's first-in-class innate defense regulator technology, dusquetide (SGX942) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (SGX945) in Behcet's Disease.

The company's Public Health Solutions business segment includes development programs for RiVax(R), its ricin toxin vaccine candidate, as well as vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax(TM), its vaccine candidate for the prevention of COVID-19. The development of these vaccine programs incorporates the use of the company's proprietary heat stabilization platform technology, known as ThermoVax(R). This business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).

The latest news and updates relating to SNGX are available in the company's newsroom at https://ibn.fm/SNGX. BioMedWire is a specialized communications platform with a focus on the latest developments in the Biotechnology, Biomedical Sciences and Life Sciences sectors. For more information, please visit https://www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.